Boston Interactome

Overview

Decoding the human protein interactome for safer, more targeted therapies.. 95% of approved medicines target proteins as isolated entities, bluntly turning them on or off.

Funding and backers

Total raised
$500k
1 round on record
Latest round
$500k
Convertible Note · Jun 2026 · 4 mo ago
The money's age
Fresh money
4 months since the last round · not hiring
Momentum
20/100
fresh money
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jun 18 Raised a round Convertible Note $500k · SEC Form D 2025 Founded
Funding rounds
RoundDateAmountInvestorsSource
Convertible Note Jun 2026 $500k — SEC Form D
Registers and programsofficial lists and records that name the company
Legal entity Boston Interactome, Inc. SEC Form D
Founders and leadersfrom filings, registers and the company's site
Oliver WeisserExecutive Officer, DirectorSEC Form D
Soon Gang ChoiExecutive Officer, DirectorSEC Form D
Similar startupsby what they do, their industry and backers
Buzzard Pharmaceuticals, a clinical-stage biotech company developing innovative IL-1 targeted therapies focused on inflammation-driven…
NumafermFounded 2017
Numaferm believes in peptides, pepteins & proteins as feedstock for better, safer & healthier products in life sciences & beyond.
Pioneering Protein Degradation for Targeted Therapies. Laigo Bio is at the forefront of a revolutionary era in biotechnology -one that…
Engineering Precision Medicines. Developing targeted therapies that address serious medical need using proprietary platform technologies…
MindpeakFounded 2018 · 11-50 employees · 7 roles
Mindpeak transforms tissue into high-dimensional data, enabling the discovery of AI-driven biomarkers that guide targeted therapies and…
Fore BiotherapeuticsSeries D $67.4M · 4 mo ago · 51-200 employees
Leading the future of targeted therapies for the hardest to treat cancers. Wednesday, October 15, 202512:00 pm ET.

Financials

Total raised
$500k
Latest round
Convertible Note
Funding rounds
1
Funding rounds
Round Announced Amount
Convertible Note 2026 $500k Details

People

Oliver Weisser
Executive Officer, Director
Soon Gang Choi
Executive Officer, Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data

Offices

Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Allston United States
HQ